ALPN Alpine Immune Sciences

Nivalis Therapeutics Inc a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis. Geographically operation of the group is functioned through United States.

As of 09/16/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/17/2015
Outstanding shares:  23,914,879
Average volume:  64,164
Market cap:   $234,604,963
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    02083G100
ISIN:        US02083G1004
Sedol:      BYX38M1
Valuation   (See tab for details)
PE ratio:   -6.97
PB ratio:   5.43
PS ratio:   13.07
Return on equity:   -77.92%
Net income %:   -190.22%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy